Perioperative systemic therapy and radiotherapy in node-positive penile squamous cell carcinoma
Current evidence on neoadjuvant and adjuvant strategies in the InPACT Er
DOI:
https://doi.org/10.5489/cuaj.9802Keywords:
penile cancer; squamous cell carcinoma; neoadjuvant chemotherapy; adjuvant chemotherapy; adjuvant radiotherapy; lymph node metastasis; InPACT; immunotherapyAbstract
Introduction: Penile squamous cell carcinoma (PSCC) is a rare but aggressive malignancy in which prognosis is largely determined by nodal involvement. In patients with node-positive disease, surgery alone is frequently insufficient, particularly in the presence of bulky inguinal metastases, pelvic nodal disease, or extranodal extension. Perioperative strategies incorporating systemic therapy and/or radiotherapy have therefore become increasingly relevant, although the evidence base remains limited and predominantly non-randomized. We aimed to critically review the available evidence on neoadjuvant chemotherapy (NAC), adjuvant chemotherapy (ACT), adjuvant radiotherapy (ART), and combined chemoradiotherapy in node-positive PSCC and to contextualize current practice within the framework of contemporary international guidelines and the ongoing InPACT trial.
Methods: Narrative review with structured literature search of PubMed/MEDLINE, EMBASE, Scopus, the Cochrane Library, and ClinicalTrials.gov covering the 15 years preceding the search date, with a targeted update through 2025. Selected phase 2 immunotherapy studies reported in 2025, including full-text publications and conference presentations (ASCO GU 2025 and ESMO 2025), were additionally included as contextual evidence for emerging perioperative strategies.
Results: Cisplatin/taxane-based NAC remains the best-established perioperative approach for selected cN2–N3 patients, with objective response rates of 50–57% and substantially longer survival in clinical responders than non-responders. Retrospective data suggest that ACT may be associated with improved survival in pN3 disease, while ART appears to contribute to locoregional control in patients with extranodal extension, with retrospective data suggesting that dose intensity may influence in-field control. Immunotherapy-based combinations have produced encouraging early-phase signals but remain preliminary and should not yet be regarded as practice-defining.
Conclusions: Current evidence supports cisplatin/taxane-based NAC as the most established perioperative strategy for chemotherapy-fit patients with cN2–N3 PSCC. ACT may be considered mainly in selected pN3 patients or in those with other high-risk pathological features after lymphadenectomy, whereas ART appears most relevant for locoregional risk reduction, particularly in the presence of inguinal extranodal extension.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:
- Post the Article on any Web site
- Translate or authorize a translation of the Article
- Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
- Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.
The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.
You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.
The CUA also requires you to warrant the following:
- That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
- That all individuals who have made a substantive contribution to the article are acknowledged;
- That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
- That the Article does not libel or violate the privacy rights of any third party.




